

# HIV Risk Among People Who Inject Drugs in New York City

Findings from the 2022 National HIV Behavioral Surveillance Study



## Background

- New York City (NYC) has a large population of people who inject drugs (PWID).
- The number of new HIV diagnoses among people with a history of injection drug use in NYC has decreased over the course of the epidemic.
  - The decrease is largely attributed to the success of sterile syringe access programs and increased safe injection practices.
- In 2022, <1% of new HIV diagnoses in NYC were among people with a history of injection drug use.
- Ongoing sexual and injection-related risk behaviors among PWID continue to persist and may be influenced by the current opioid overdose epidemic.



## National HIV Behavioral Surveillance (NHBS)

- Ongoing, cyclical study of three priority populations at increased risk for HIV: men who have sex with men (MSM), PWID, and heterosexually active persons at increased risk of HIV infection (HET).
  - Currently conducted in 20 cities throughout the U.S.
  - Funded by CDC, designed collaboratively
  - Cross-sectional study design
  - Anonymous, structured interview and optional HIV testing
- Data were collected for the sixth cycle among PWID ("PWID2022") from September to December 2022.



### NHBS-PWID2022 Objectives

### Seroprevalence

- Assess the prevalence of and trends in HIV infection and awareness of HIV infection.

#### Behaviors

 Assess the prevalence of and trends in behaviors and social determinants that increase the risk of HIV acquisition and transmission, including sexual and drug use behaviors.

### HIV testing and treatment

Describe utilization of and trends in HIV testing, linkage to care, and antiretroviral therapy.

#### Prevention

- Assess the exposure to and use of prevention services, including HIV pre-exposure prophylaxis (PrEP).
- Identify gaps in prevention and missed opportunities for prevention interventions.

# NHBS-PWID2022 Eligibility Criteria

- At least 18 years old
- Resident of NYC Metropolitan Statistical Area (MSA) which includes NYC,
   Westchester County, Rockland County, Orange County and some counties in New Jersey.
- Injected non-prescription drugs in the past 12 months
- Able to complete the interview in English or Spanish
- Did not previously participate in that current NHBS-PWID cycle




### Respondent-Driven Sampling (RDS) Recruitment Method

- 1. Study team recruited a small number of initial participants ("seeds") through community outreach.
  - To increase the proportion of young PWID, initial seeds were 18-39 years old.
- 2. Seeds participated in the study and then recruited up to five peers in their social networks.
- 3. If eligible, those recruited peers participated and each recruited up to an additional five peers until the sample size was met.
  - Recruitment chains were continually monitored to ensure demographic representativeness.
- 4. Incentives were provided for completing the survey, HIV testing, hepatitis C testing, and peer recruitment.




## NYC NHBS-PWID2022 Study Sample





### Recruitment Chain Diagram for NYC NHBS-PWID2022



Each node represents a study participant. Linking lines show recruitment chains, initiated by 8 productive seeds (represented by bolded square nodes).



### Statistical Analyses

- Weighted analyses were conducted with RDS Analyst (RDS-A) software. Data were weighted to take into account network size.
  - Those with large network sizes have a higher probability of selection.
- An advantage of RDS is that if methodological assumptions are met, RDS-A may estimate proportions that are generalizable to the larger population.



### Statistical Analyses

- Basic descriptive frequencies of behaviors, testing, and prevention services were calculated.
- Since seeds are not randomly recruited, they were excluded from analyses.
- Since awareness of HIV status influences risk, those who self-reported an HIV-positive status (n=7) were excluded from behavioral risk analyses.



# Demographics

# Demographics

NYC NHBS-PWID2022, n=72

Race/Ethnicity		Age Group (In Years)	
Hispanic or Latino/a	36%	18-29	8%
White	36%	30-39	28%
Black	27%	40-49	21%
Other	1%	≥ 50	43%
Self-Identified Gender		Birthplace	
Male	96%	U.S.	91%
Female	3%	Outside of U.S.	9%
Transgender	1%		

# Demographics

NYC NHBS-PWID2022, n=72

Annual Household Income		Education Level	
< \$10,000	44%	< High school	64%
≥ \$10,000	56%	≥ High School	36%
Area of Residence		Homelessness*	
Bronx	10%	Homeless	69%
Brooklyn	23%	Not Homeless	31%
Manhattan	27%		
Queens	9%		
Outside of NYC, in MSA	31%		

<sup>\*</sup>Past 12 months

# Injection Drug Use

## Lifetime Injection History

NYC NHBS-PWID2022, n=72

**Median Age in Years at First Injection** 


24

**Median Age in Years at Interview** 

47


**Median Years Since First Injection** 

19




### Frequency of Drugs Injected, Past 12 Months

NYC NHBS-PWID2022, n=72



### Syringe Reuse and Sharing by Self-Reported HIV Status, Past 12 Months

NYC NHBS-PWID2022, n=72




Syringe reuse: not using a new, sterile needle when injecting.

Receptive sharing: using a needle after someone else injected with it.

Distributive sharing: giving a needle to someone else after using it to inject with.

### Other Equipment Sharing by Self-Reported HIV Status, Past 12 Months

NYC NHBS-PWID2022, n=72




Receptive sharing: using a needle after someone else injected with it. Distributive sharing: giving a needle to someone else after using it to inject with.

# Alcohol and Non-Injection Drug Use

# Alcohol Use, Past 30 Days


NYC NHBS-PWID2022, n=72



Binge drinking: consuming at least 5 drinks for men or 4 drinks for women in one sitting. Participants who identify as transgender were excluded (n=2).

### Frequency of Non-Injection Drug Use, Past 12 Months


NYC NHBS-PWID2022, n=72



# Overdose and Overdose Prevention

## Experienced a Nonfatal Overdose, Past 12 Months

NYC NHBS-PWID2022, n=72




Overdose: passed out, turned blue, or stopped breathing from using drugs.

<sup>\*</sup>Among those who used heroin or opioids in past 12 months (n=68).

### Overdose Prevention


NYC NHBS-PWID2022, n=72



<sup>\*</sup>Among those who reported receiving a naloxone kit in the past 12 months (n=59).

### Awareness and Likelihood of Going to an Overdose Prevention Center (OPC)


NYC NHBS-PWID2022, n=72



# Sexual Activity

## Sexual Partner Type, Past 12 Months

NYC NHBS-PWID2022, n=66 (HIV-/Unknown Status)\*



<sup>\*</sup>Sexual behavior questions were not asked among those who identify as transgender (n=2).


Main partner: a person the respondent had sex with and who they felt committed to above anyone else.

Casual partner: a person the respondent had sex with but who they did not feel committed to or did not know very well.

Exchange sex: provided or received money or drugs in exchange for sex.

### Sexual Behavior, Past 12 Months

NYC NHBS-PWID2022, n=66 (HIV-/Unknown Status)\*




<sup>\*</sup>Sexual behavior questions were not asked among those who identify as transgender (n=2).

# Health Care and HIV Prevention

## Health Care and Drug Treatment, Past 12 Months


NYC NHBS-PWID2022, n=72



<sup>\*</sup>Among those who reported opioid use in the past 12 months (n=68). Medication treatment included medicines like methadone, buprenorphine, Suboxone or Subutex.


### HIV Testing History Among PWID in Past Three NHBS-PWID Cycles

NYC NHBS-IDU4 (2015), IDU5 (2018), and PWID2022 (HIV-/Unknown Status across all cycles)




# Pre-Exposure Prophylaxis (PrEP) Awareness and Use

NYC NHBS-PWID2022, n=66 (HIV-/Unknown Status)



### Use of HIV Prevention Services by Self-Reported HIV Status, Past 12 Months

NYC NHBS-PWID2022, n=72



Individual counseling: one-on-one conversation with an outreach worker, counselor, or prevention program worker about ways to prevent HIV. Does not include counseling as part of an HIV test. Group counseling: any organized session involving a small group of people to discuss ways to prevent HIV. Does not include discussions had with friends.

# Conclusions

### Summary

- Heroin remains the most common drug injected in NYC.
- During the COVID-19 pandemic, there was reduced access to harm reduction services in NYC. This may have impacted syringe access and injection-related behaviors. Among PWID who reported an HIV-negative or unknown status, 67% reported any sharing of receptive equipment.
- Sexual behaviors pose a risk to PWID, with 57% reporting any condomless vaginal or anal sex in the past 12 months.



### Summary

- Among PWID who reported an HIV-negative or unknown status, 99% of participants reported that they took an HIV test in their lifetime, however, only 68% of PWID took an HIV test in the past 12 months.
- Among PWID who reported an HIV-negative or unknown status, awareness of PrEP (58%) and its use (5%) remains historically lower than in other priority populations.
- Awareness of OPCs was high (84%), with 89% of PWID being likely to go to an OPC if nearby.



### Strengths

- NHBS is the only ongoing national data collection system for biobehavioral HIV surveillance.
- A standardized survey and protocol is implemented nationally.
- RDS can reach underrepresented populations who may not access treatment programs and other institutionalized settings.
- Local questions were developed to explore relevant themes specific to PWID in NYC.
- HIV status was confirmed via a rapid-rapid testing algorithm.



### Limitations

- Restrictions related to COVID-19 delayed the implementation of data collection, which limited the sample size.
- Findings may not be representative of the PWID population in NYC.
- Only those who are socially-networked to other PWID can be recruited through RDS.
- Survey data were collected by self-report and may be biased by recall error or social desirability.



### NYC NHBS-PWID2022 Team

### **NYC Health Department**

- Principal Investigator Alexis Rivera, MPH
- Project Director
   Kristina Rodriguez, DrPH, MPH
- Study Operations Supervisor Pablo 'Tony' Martinez
- Data Collection Team

Cathryn Guzman

**Brittney McClean** 

**Ronald Miller** 

Joshua Morales

Clarence 'Angel' Rodriguez

Karina Torres

#### **CDC Team**

Project Officers
 Christine Agnew-Brune, PhD, MPH
 Dita Broz, PhD, MPH

CDC Grant: 5 NU62PS924775



### Contact

### Kristina Rodriguez, DrPH, MPH

**NHBS Project Director** 

HIV Epidemiology Program

Bureau of Hepatitis, HIV, and Sexually Transmitted Infections

NYC Department of Health and Mental Hygiene

Email: <a href="mailto:krodriguez2@health.nyc.gov">krodriguez2@health.nyc.gov</a>

